Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: Clin Cancer Res. 2020 Jul 14;26(19):5140–5152. doi: 10.1158/1078-0432.CCR-20-1695

Table 2.

Neoadjuvant and adjuvant pembrolizumab-related adverse events

Neoadjuvant Phase Post-Surgery and Adjuvant Phase
All Patients (N=36) Patients Treated with Adjuvant Pembrolizumab (N=12)*
Event Grades 1–2 Grades 3–4 Grades 1–2 Grades 3–4
N (%) N (%) N (%) N (%)
Fatigue 2 (6) 0 (0) 2 (17) 0 (0)
Hypothyroidism 0 (0) 0 (0) 3 (25) 1 (8)
Fever 1 (3) 0 (0) 0 (0) 0 (0)
Tumor flare 1 (3) 0 (0) 0 (0) 0 (0)
AST increase 0 (0) 0 (0) 1 (8) 0 (0)
ALT increase 0 (0) 0 (0) 1 (8) 0 (0)
Alk. Phos. increase 0 (0) 0 (0) 1 (8) 0 (0)
Diarrhea 0 (0) 0 (0) 1 (8) 0 (0)
*

No post-surgery/adjuvant phase pembrolizumab-related adverse events occurred among patients who did not receive adjuvant pembrolizumab.